Publications by authors named "Darryl Boehm"

Claim this Profile
A
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Pam Takhar, Marc Geirnaert, Scott Gavura, Jaclyn Beca, Rebecca E Mercer, Darryl Boehm

Curr Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm

Curr Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
Daniel Moldaver, Manjusha Hurry, William K Evans, Parneet K Cheema, Randeep Sangha, Darryl Boehm

Lung Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
Daniel Moldaver, Manjusha Hurry, William K Evans, Parneet K Cheema, Randeep Sangha, Darryl Boehm

Lung Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis.
Reka Pataky, David A Tran, Andrea Coronado, Riaz Alvi, Darryl Boehm

CMAJ Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis